关于公司第五届监事会第三次会议决议的公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 海利尔药业集团股份有限公司(以下简称"公司")第五届监事会第三次会议 于 2024 年 2 月 27 日 10：00 在青岛市城阳区国城路 216 号，公司五楼会议室召 开。会议通知于 2024 年 2 月 23 日发出，应到监事 3 名，实到监事 3 名，公司董 事会秘书列席会议，符合《中华人民共和国公司法》和《海利尔药业集团股份有 限公司章程》的有关规定，会议合法有效。会议由陈萍先生主持，经与会监事充 分审议，本次会议形成如下决议： 二、 监事会会议审议情况 1、审议通过《关于 2021 年限制性股票激励计划预留授予部分第二期解锁 条件成就的议案》 表决结果：3 票同意，0 票反对，0 票弃权。 证券代码：603639 证券简称：海利尔 公告编号：2024-003 海利尔药业集团股份有限公司 本激励计划预留授予部分第二期解除限售条件已经成就，本次解除限售事项 符合《管理办法》与《激励计划（草案）》的有关规定。公 ...

证券代码：603639 证券简称：海利尔 公告编号：2024-004 海利尔药业集团股份有限公司 关于2021年限制性股票激励计划预留授予部分第二期解锁 条件成就的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司 2021 年限制性股票激励计划预留授予部分的限制性股票第二期解 锁条件已成就，符合解除限售条件的激励对象共 83 名，可解除限售的限制性股 票数量为 225,030 股，占目前公司总股本的 0.066%。 本次限制性股票待相关解除限售上市申请完成后，公司将发布相关解锁 暨上市的公告，敬请投资者注意。 2024 年 2 月 27 日，海利尔药业集团股份有限公司（以下简称"公司"）召 开第五届董事会第三次会议，审议通过了《关于 2021 年限制性股票激励计划预 留授予部分第二期解锁条件成就的议案》，现就相关事项说明如下： 5、2021 年 5 月 12 日，公司披露了《关于 2021 年限制性股票激励计划首次 授予结果的公告》（公告编号：2021-034），确定限制性股票登记日为 2021 年 ...

证券代码：603639 证券简称：海利尔 公告编号：2024-005 海利尔药业集团股份有限公司 关于公司完成工商变更登记并换发营业执照的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 海利尔药业集团股份有限公司（以下简称"公司"）于 2023 年 10 月 27 日召 开第五届董事会第二次会议，审议通过了《关于修改公司章程的议案》，鉴于公 司 2021 年限制性股票激励计划 31 名激励对象已不符合激励条件，其持有的已获 授但未解锁部分限制性股票共 22.435 万股需要进行回购注销，公司总股本 340,230,446 股将减少至 340,006,096 股，公司注册资本由原来的 340,230,446 元变更为 340,006,096 元，相关内容详见公司于 2023 年 10 月 28 日在上海证券 交易所网站（www.sse.com.cn）披露的《关于修改公司章程的公告》（公告编号： 2023-056）。 近日，公司完成了工商变更登记手续，并取得了青岛市行政审批服务局换发 的《营业执照》，具体内容如下： 统一社会 ...

北京市金杜（青岛）律师事务所 关于海利尔药业集团股份有限公司 2021 年限制性股票激励计划回购注销部分已授予限制性股票事项的 法律意见书 致：海利尔药业集团股份有限公司 北京市金杜（青岛）律师事务所（以下简称金杜或本所）受海利尔药业集团 股份有限公司（以下简称海利尔或公司）委托，作为其 2021 年限制性股票激励计 划（以下简称本次股权激励计划或本计划）的专项法律顾问。本所根据《中华人 民共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证 券法》）、中国证券监督管理委员会（以下简称中国证监会）《上市公司股权激励管 理办法》（以下简称《管理办法》）等法律、行政法规、部门规章及规范性文件（以 下简称法律法规）和《海利尔药业集团股份有限公司章程》（以下简称《公司章程》） 的有关规定，以及公司于 2021 年 3 月 6 日公告的《海利尔药业集团股份有限公司 2021 年限制性股票激励计划（草案）》（以下简称《限制性股票激励计划》），就公 司本次回购注销部分已授予限制性股票（以下简称本次回购注销）所涉及的相关 事宜出具本法律意见书。 为出具本法律意见书，金杜依据《律师事务所从事证券法律业务 ...

证券代码：603639 证券简称：海利尔 公告编号：2024-001 海利尔药业集团股份有限公司 关于股权激励限制性股票回购注销实施的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 回购注销原因：根据公司 2021 年限制性股票激励计划相关规定，公司部 分激励对象已不符合激励条件，公司拟对该激励对象已获授但尚未解锁的限制性 股票进行回购注销。 本次注销股份的有关情况： | 回购股份数量 | 注销股份数量 | | 注销日期 | | | | --- | --- | --- | --- | --- | --- | | 224,350 股 | 224,350 | 股 | 2024 1 月 | 年 | 5 日 | 一、本次限制性股票回购注销的决策与信息披露 （三）回购注销安排 根据公司 2021 年第一次临时股东大会的授权，2023 年 10 月 27 日，公司召 开第五届董事会第二次会议和第五届监事会第二次会议，审议通过《关于回购注 销部分激励对象已获授但尚未解锁的限制性股票的议案》。公司部分激励对象已 不再满足 ...

证券代码：603639 证券简称：海利尔 公告编号：2023-058 海利尔药业集团股份有限公司 关于持股 5%以上股东及董事、高级管理人员集中竞价 减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 大股东及董事、高级管理人员持股的基本情况 本次减持计划实施前，海利尔药业集团股份有限公司（以下简称"公司"） 股东青岛合意投资中心（有限合伙）持有公司股份 17,849,951 股，占公司总股 本的 5.2464%；原董事李建国先生持有公司股份 144,480 股，占公司总股本的 0.0425%；董事、高级管理人员刘玉龙先生持有公司股份 193,640 股，占公司总 股本的 0.0569%；高级管理人员迟明明女士持有公司股份 14,200 股，占公司总 股本的 0.0042%。 集中竞价减持计划的实施结果情况 公司于 2023 年 4 月 28 日披露了《关于持股 5%以上股东及董事、高级管理 人员集中竞价减持股份计划公告》（公告编号：2023-026）。截止本公告披露日， 本次减持计划时 ...

Group 1: Meeting Details - The meeting is scheduled for November 8, 2023, from 15:00 to 17:00 [3] - The meeting will be held online via the "Panorama Roadshow" website [3] - Investors can participate through the "Panorama Roadshow" website, WeChat public account, or by downloading the Panorama Roadshow APP [4] Group 2: Purpose of the Meeting - The meeting aims to provide a comprehensive understanding of the company's Q3 2023 performance and financial status [2] - Topics of discussion will include corporate governance, development strategy, operational status, financing plans, equity incentives, and sustainable development [2] Group 3: Participants - Key participants include Chairman and General Manager Ge Jiacheng, Financial Director Liu Yulong, Secretary of the Board Chi Mingming, and Independent Director Yang Aiyi [4] Group 4: Contact Information - Contact person for inquiries is Chi Mingming, reachable at phone number 0532-58659169 and email hailir@hailir.cn [4] Group 5: Additional Information - After the meeting, investors can view the meeting's proceedings and key content on the "Panorama Roadshow" website [5]

Major Financial Data [Major Accounting Data and Financial Indicators](index=1&type=section&id=Major%20Accounting%20Data%20and%20Financial%20Indicators) The company's Q3 2023 operating revenue grew 5.25% and net profit attributable to parent company shareholders increased 9.96%, with year-to-date operating cash flow up 90.99% Key Financial Indicators for Q3 and YTD 2023 | Indicator | Current Reporting Period (Q3) | Year-to-Date (YTD) | Year-over-Year Change (YTD) (%) | | :--- | :--- | :--- | :--- | | Operating Revenue (CNY) | 1,044,000,000 | 3,707,000,000 | -2.51% | | Net Profit Attributable to Shareholders of the Listed Company (CNY) | 111,000,000 | 442,000,000 | 2.70% | | Net Profit Attributable to Shareholders of the Listed Company (Excluding Non-Recurring Items) (CNY) | 98,000,000 | 476,000,000 | -1.42% | | Net Cash Flow from Operating Activities (CNY) | Not Applicable | 579,000,000 | 90.99% | | Basic Earnings Per Share (CNY/share) | 0.33 | 1.30 | 3.13% | | Total Assets (Period-End) (CNY) | 6,401,000,000 | 6,401,000,000 | 9.65% (compared to previous year-end) | | Shareholders' Equity Attributable to Shareholders of the Listed Company (Period-End) (CNY) | 3,351,000,000 | 3,351,000,000 | 4.33% (compared to previous year-end) | [Non-Recurring Gains and Losses Items and Amounts](index=2&type=section&id=Non-Recurring%20Gains%20and%20Losses%20Items%20and%20Amounts) During Q3 2023, the company's total non-recurring gains and losses amounted to **13.63 million CNY**, primarily from fair value changes of financial assets/liabilities, while year-to-date, the total was **-33.28 million CNY**, mainly due to accumulated fair value losses Major Non-Recurring Gains and Losses Items (Unit: CNY) | Item | Amount for Current Period (CNY) | Amount Year-to-Date (CNY) | | :--- | :--- | :--- | | Gains and Losses from Fair Value Changes | 13,010,220.65 | -39,066,554.87 | | Government Grants Recognized in Current Profit/Loss | 2,022,094.54 | 8,983,666.60 | | Gains and Losses from Disposal of Non-Current Assets | -1,473,532.82 | -1,948,164.86 | | **Total** | **13,634,591.44** | **-33,281,067.17** | [Changes and Reasons for Major Accounting Data and Financial Indicators](index=4&type=section&id=Changes%20and%20Reasons%20for%20Major%20Accounting%20Data%20and%20Financial%20Indicators) Significant period-end changes include a 60.21% increase in accounts receivable, a 161.43% rise in construction in progress, a 93.87% decrease in financial expenses, and a 90.99% growth in net cash flow from operating activities Changes and Reasons for Major Financial Indicators | Item | Change (%) | Primary Reason | | :--- | :--- | :--- | | Accounts Receivable | 60.21 | Shipments during peak sales season not yet due for payment | | Construction in Progress | 161.43 | Increased investment in Hengning Project | | Financial Expenses | -93.87 | Impact of exchange rate fluctuations | | Net Cash Flow from Operating Activities | 90.99 | Timely collection of sales proceeds | Shareholder Information [Shareholder Holdings](index=5&type=section&id=Total%20Number%20of%20Common%20Shareholders%2C%20Preferred%20Shareholders%20with%20Restored%20Voting%20Rights%2C%20and%20Top%20Ten%20Shareholders%27%20Holdings) As of the period-end, the company had 13,469 common shareholders, with the top three shareholders, Zhang Aiying, Ge Yaolun, and Ge Jiacheng, acting in concert and collectively holding over 59% of shares, indicating a relatively concentrated equity structure - As of the period-end, the company had **13,469** common shareholders[13](index=13&type=chunk) Top Three Shareholders' Holdings | Shareholder Name | Holding Percentage (%) | Related Party Relationship | | :--- | :--- | :--- | | Zhang Aiying | 37.40 | Concerted Action Party | | Ge Yaolun | 18.23 | Concerted Action Party | | Ge Jiacheng | 3.74 | Concerted Action Party | Other Reminders [Other Important Operating Information Requiring Investor Attention](index=6&type=section&id=Other%20Important%20Operating%20Information%20Requiring%20Investor%20Attention) The company has no other significant operating information requiring special investor attention during the current reporting period - The company has no other significant operating information requiring special investor attention during the current reporting period[15](index=15&type=chunk) Quarterly Financial Statements [Type of Audit Opinion](index=6&type=section&id=Type%20of%20Audit%20Opinion) The financial statements for this quarter are unaudited - The company's Q3 2023 financial statements are unaudited[15](index=15&type=chunk) [Financial Statements](index=6&type=section&id=Financial%20Statements) This section presents the company's consolidated balance sheet as of September 30, 2023, and the consolidated income statement and cash flow statement for January-September 2023 [Consolidated Balance Sheet](index=6&type=section&id=Consolidated%20Balance%20Sheet) As of September 30, 2023, the company's total assets were **6.401 billion CNY**, up 9.65% from year-end; total liabilities were **3.050 billion CNY**, up 16.17%; and shareholders' equity attributable to listed company shareholders was **3.351 billion CNY**, up 4.33%, with an asset-liability ratio of 47.65% Key Balance Sheet Items (As of September 30, 2023) | Item | Sep 30, 2023 (CNY) | Dec 31, 2022 (CNY) | Change (%) | | :--- | :--- | :--- | :--- | | Total Assets | 6,401,025,895.36 | 5,837,602,158.84 | 9.65 | | Total Liabilities | 3,050,076,804.11 | 2,625,649,238.99 | 16.17 | | Shareholders' Equity Attributable to Shareholders of the Listed Company | 3,350,949,091.25 | 3,211,952,919.85 | 4.33 | - Asset growth primarily stemmed from **accounts receivable (+60.21%)** and **construction in progress (+161.43%)**, while liability growth was mainly driven by short-term borrowings, notes payable, and taxes payable[10](index=10&type=chunk)[16](index=16&type=chunk)[17](index=17&type=chunk) [Consolidated Income Statement](index=9&type=section&id=Consolidated%20Income%20Statement) For the first three quarters of 2023, the company reported total operating revenue of **3.707 billion CNY**, a 2.51% year-over-year decrease, and net profit attributable to parent company shareholders of **442 million CNY**, a 2.70% increase, driven by effective control over operating costs and financial expenses, alongside a 20.67% rise in R&D expenses Key Income Statement Items (First Three Quarters of 2023) | Item | First Three Quarters of 2023 (CNY) | First Three Quarters of 2022 (CNY) | Year-over-Year Change (%) | | :--- | :--- | :--- | :--- | | Total Operating Revenue | 3,707,271,408.11 | 3,802,550,062.12 | -2.51 | | Total Operating Costs | 3,097,495,540.35 | 3,180,955,439.46 | -2.62 | | Net Profit Attributable to Parent Company Shareholders | 442,221,155.56 | 430,591,861.86 | 2.70 | | Basic Earnings Per Share (CNY/share) | 1.30 | 1.26 | 3.17 | - Research and development expenses increased **20.67%** year-over-year to **193 million CNY**, while financial expenses shifted from **-99 million CNY** in the prior year to **-6 million CNY** due to exchange rate fluctuations[20](index=20&type=chunk) [Consolidated Cash Flow Statement](index=11&type=section&id=Consolidated%20Cash%20Flow%20Statement) In the first three quarters of 2023, net cash flow from operating activities significantly increased by **90.99%** to **579 million CNY**, primarily due to timely collection of sales proceeds and reduced procurement outlays, while net cash outflows from investing and financing activities were **544 million CNY** and **94 million CNY**, respectively, resulting in a period-end cash and cash equivalents balance of **281 million CNY** Key Cash Flow Statement Items (First Three Quarters of 2023) | Item | First Three Quarters of 2023 (CNY) | First Three Quarters of 2022 (CNY) | Year-over-Year Change (%) | | :--- | :--- | :--- | :--- | | Net Cash Flow from Operating Activities | 579,122,250.94 | 303,218,727.76 | 90.99 | | Net Cash Flow from Investing Activities | -544,011,574.81 | -555,269,883.47 | Not Applicable | | Net Cash Flow from Financing Activities | -94,288,754.00 | 327,499,464.15 | Not Applicable | | Cash and Cash Equivalents at Period End | 280,678,286.82 | 605,750,856.27 | -53.68 | - The strong growth in operating cash flow was primarily driven by a **15.52%** year-over-year decrease in cash paid for goods and services, while cash received from sales of goods and services remained largely stable[25](index=25&type=chunk)[26](index=26&type=chunk)

证券代码：603639 证券简称：海利尔 公告编号：2023-056 除上述条款外，《公司章程》其他条款内容不变，最终以工商部门核准备案 为准。 上述修订《公司章程》及相应注册资本变更办理工商变更登记的事项已经公 司 2023 年第一次临时股东大会授权，无需再次提交公司股东大会审议。 海利尔药业集团股份有限公司 关于修改公司章程的公告 修 订 后 的 全 文 请 见 公 司 于 2023 年 10 月 28 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）披露的《公司章程》。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 特此公告。 海利尔药业集团股份有限公司（以下简称"公司"）于 2023 年 10 月 27 日 召开了第五届董事会第二次会议，审议通过了《关于修改公司章程的议案》。同 意公司减少注册资本，并对《公司章程》进行修订。具体情况如下： 海利尔药业集团股份有限公司董事会 鉴于公司2021年限制性股票激励计划31名激励对象因离职已不符合激励条 件，其持有的已获授但未解锁部分限制性股票共 2 ...